2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market

CNBC Published Updated Stocks
Sign in to save

Affected assets and topics

MARKET

Why it matters

The GLP-1 market is expected to undergo significant changes in 2026 with the introduction of obesity pills from Novo Nordisk and Eli Lilly, potentially reshaping the industry.

Article tone

Neutral How the article is written, as reported by the source.

Expected market reaction

Bullish Confidence 90% How confidence is read Horizon: Short term Impact: Moderate

Market impact analysis based on bullish sentiment with 90% confidence.

Evidence trail

Evidence
Source CNBC
Claim 2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market
AI inference Bullish · 90%
Generated 2026-01-10 13:00

AI provenance

Analysed by Llama 3.1 8B Instant (Groq) Methodology v1.0 Generated
Technical identifiers
Provider tag
groq-llama-3.1-8b-instant
Analysis version
groq-llama-3.1-8b-instant
Article id
31055

Original source

Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for U.S. approval later this year.

Read the full article on CNBC

Original article published by CNBC on January 10, 2026. Analysis and insights provided by AnalystMarkets AI.

Related coverage